Point-of-care tests for fentanyl.

Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified. This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law.